Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 1Prostate Cancer Non-Metastatic 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Has results × darolutamide × Clear all
NCT04736199 2026-02-27

ARANOTE

Bayer

Phase 3 Completed
669 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT02799602 2025-12-04

ARASENS

Bayer

Phase 3 Completed
1,306 enrolled 25 charts 2 FDA
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT04237584 2022-10-07

ESCALATE

MANA RBM

Phase 3 Terminated
23 enrolled 11 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02200614 2022-06-28

ARAMIS

Bayer

Phase 3 Completed
1,509 enrolled 13 charts 1 FDA
Genitourinary

Prostate Cancer Non-Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡